{"prompt": "['2018N394263_00', '2016N293064_ 01', 'CONFIDENTIAL', '-', '205864', 'SPONSOR SIGNATORY:', 'PPD', '17-May + 2017', 'PPD', 'Aili Lazaar, MD', 'Date', 'Clinical Development Director', 'Respiratory Therapy Area Unit', 'PPD', '2']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', 'DOCUMENT HISTORY', 'Document', 'Date', 'Amendment 1', '17-May-2017', 'Original Protocol', '21-Mar-2017', 'Amendment 1 17-May-2017', 'Overall Rationale for the Amendment: This amendment excludes the enrolment of', 'women of childbearing potential and clarifies the testing required for determination of', 'post menopausal status in specific situations.', 'Section #', 'Description of Change', 'Brief Rationale', 'and Name', 'Table 1 -', 'Remove pregnancy testing', 'Not required as no longer enrolling', 'Schedule of', 'WOCBP', 'Activities', 'Added missing check', 'marks', 'Error in original protocol', 'Updated screening period', 'Required to allow for screening lab', 'tests', 'Section 6.1', 'Update to only allow females to', 'To remove additional burden on female', 'Inclusion', 'participate if they are not women of', 'subjects of childbearing potential requiring', 'Criteria', 'childbearing potential (WOCBP)', 'additional visits for pregnancy testing only.', 'Section 12.2', 'Update Table 6 - Protocol-', 'Removed pregnancy testing based on the', '- Appendix 2', 'Required Safety Laboratory', 'exclusion of WOCBP', 'Clinical', 'Assessments to remove pregnancy', 'Laboratory', 'testing', 'Tests', 'Section 12.5', 'Adding clarification on', 'Current wording in template is not', '- Appendix 5', 'determination of post', 'clear on testing required', 'Contraceptive', 'menopausal state in the', 'absence of 12 months of', 'Clarification of wording', 'Guidance and', 'Collection of', 'amenorrhea', 'Pregnancy', 'Updated wording to be in', 'Information', 'line with exclusion of', 'WOCBP', '3']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'TABLE OF CONTENTS', 'PAGE', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE', '3', '1. SYNOPSIS', '7', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', '9', '3.', 'INTRODUCTION', '12', '3.1.', 'Study Rationale', '12', '3.2.', 'Background', '13', '3.3.', 'Benefit/Risk Assessment', '14', '3.3.1.', 'Risk Assessment', '15', '3.3.2.', 'Benefit Assessment', '19', '3.3.3.', 'Overall Benefit:Risk Conclusion', '19', '4. OBJECTIVES AND ENDPOINTS', '20', '5.', 'STUDY DESIGN', '21', '5.1.', 'Overall Design', '21', '5.2.', 'Number of Participants', '21', '5.3.', 'Participant and Study Completion', '22', '5.4.', 'Scientific Rationale for Study Design', '22', '5.5.', 'Dose Justification', '22', '6.', 'STUDY POPULATION', '23', '6.1.', 'Inclusion Criteria', '23', '6.2.', 'Exclusion Criteria', '24', '6.3.', 'Lifestyle Restrictions', '26', '6.3.1.', 'Meals and Dietary Restrictions', '26', '6.3.2.', 'Activity', '27', '6.4.', 'Screen Failures', '27', '7. TREATMENTS', '27', '7.1.', 'Treatments Administered', '28', '7.1.1.', 'Medical Devices', '28', '7.2.', 'Dose Modification', '29', '7.3.', 'Method of Treatment Assignment', '29', '7.4.', 'Blinding', '29', '7.5.', 'Preparation/Handling/Storage/Accountability', '29', '7.6.', 'Treatment Compliance', '30', '7.7.', 'Concomitant Therapy', '30', '7.8.', 'Treatment after the End of the Study', '32', '8.', 'DISCONTINUATION CRITERIA', '32', '8.1.', 'Discontinuation of Study Treatment', '32', '8.1.1.', 'Liver Chemistry Stopping Criteria', '32', '8.1.2.', 'QTc Stopping Criteria', '33', '8.1.3.', 'Neutrophil Stopping Criteria', '34', '8.1.4.', 'Temporary Discontinuation', '34', '8.1.5.', 'Study Treatment Restart', '34', '4']\n\n###\n\n", "completion": "END"}